The thesis
PanicFade v4 is a bet on human overreaction. Its premise, grounded in recent sentiment-feedback research (arXiv:2509.11970 and corroborating work), is that negative headline shocks are systematically overdone and tend to revert toward fundamentals. The strategy waits for a confluence of signals — sentiment below −0.4, RSI14 under 35, and price beneath its SMA20 — then buys the panic in a universe of 24 blue-chip names spanning tech, financials, healthcare, and staples. It sizes into the fear rather than away from it.
The exit logic is symmetric and disciplined: take the reversion when RSI14 reclaims 50 or price recovers its SMA20, but hard-stop on fresh lows under continued negativity, treating persistent weakness as a genuine fundamental break rather than a fadeable dip. This is the crucial guardrail for any contrarian system — the difference between buying a dip and catching a falling knife.
Validation and backtest
The walk-forward validation is the strongest part of the story. Across four out-of-sample folds spanning September 2021 to August 2026, all four were positive (1.6%, 3.9%, 10.1%, 21.7%), with a Probabilistic Sharpe Ratio of 0.985 and a Deflated Sharpe of 0.56 across 27 trials. The deflated figure matters: it accounts for the multiple configurations tested, and a positive DSR after that penalty is a meaningful signal against overfitting.
The headline backtest returned 37.93% (final equity $13,793 on a ~$10k base) over 1,233 trading days — a Sharpe of 0.96, a contained 9.3% max drawdown, and a healthy 62.88% win rate across 530 trades.
The caveats
Balance demands scrutiny. That 37.93% translates to a CAGR of just 6.79% over roughly three and a half years — respectable risk-adjusted, but not a number that outruns a broad index. Turnover is heavy at 5,807%, so execution quality and fees are not incidental. Most notably, fold performance is steeply back-loaded: fold 1 posted a Sharpe of 0.19, fold 4 a Sharpe of 2.44. That recency skew flatters the aggregate out-of-sample Sharpe and deserves a skeptical eye — the recent regime may simply have suited the strategy.
Live activity: waiting for a reason
The live paper account tells its own story. Since a single 10-share WMT buy on 28 August (at $103.12), every scheduled run from 4 to 11 September executed zero trades and rejected zero candidates. The book sits at roughly $8,959 cash against a total near $10,028 — essentially flat, essentially idle.
This is not a malfunction; it is the thesis working as designed. PanicFade only acts when panic is present, and calm, grinding markets simply do not trigger it. That patience is a strength — no forced trades, no manufactured signals — but it is also a reminder that this is a specialist tool. It earns its keep in dislocations, and until one arrives, it is content to wait in cash.